- Primary research
- Open Access
Dimethylsulfoxide excerbates cisplatin-induced cytotoxicity in Ehrlich ascites carcinoma cells
Cancer Cell International volume 15, Article number: 104 (2015)
Cisplatin (CIS) is a potent antineoplastic agent with high therapeutic efficacy against many kinds of tumors. Its use is limited by its nephrotoxicity. The aim of this work was to minimize cisplatin effective dose and the possible reduction of its severe side effects. The present study was designed to assess the role of sulfur containing agent dimethyl sulfoxide (DMSO) on sensitization of mammary carcinoma, Ehrlich ascites carcinoma (EAC), to the action of cisplatin and at the same time the possible protective effect against cisplatin induced nephrotoxicity in experimental animals.
To evaluate these effects we have explored the cisplatin effect on the survival time of tumor-bearing animals, tumor weight, cisplatin cellular uptake, apoptosis induction and cell cycle distribution and renal function in presence and absence of DMSO.
Cisplatin at dose of 4.5 mg/kg increased the mean survival time of tumor bearing mice to 37 days compared with tumor bearing control mice. Pretreatment of tumor bearing mice with DMSO 50 % (2 ml/kg equal to 1 gm/kg) 2 h. before cisplatin showed a significant increase in their mean survival time 43 days compared to cisplatin treated animals. DMSO pretreatment retained rat’s serum urea and creatinine levels to normal compared to animals treated with cisplatin alone.
DMSO pretreatment enhanced the cytotoxic activity of cisplatin against the growth of EAC in vivo and showed protective effects against cisplatin-induce nephrotoxicity.
Cisplatin is one of the most active cytotoxic agents in clinical use that has proven efficacy against numerous human solid malignancies such as bladder, cervical, head and neck, esophageal, and small cell lung cancer . However, some tumors such as colorectal and non-small cell lung cancers have intrinsic resistance to cisplatin, while others such as ovarian or small cell lung cancers develop acquired resistance after the initial treatment . Recently, the cisplatin clinical usefulness is limited by chemoresistance and its side effects such as ototoxicity and nephrotoxicity . Chemosensitization is one strategy to overcome chemoresistance. It is based on the use of one drug or natural products to enhance the efficacy of antineoplastic drugs by modulating one or more mechanisms of resistance. DMSO is an organo-sulfur compound with a reactive oxygen species scavenger . Dimethyl sulfoxide has many chemical properties make it suitable as pharmaceutical carrier for many drugs, electrolytes and other molecules [5–7]. Uribe et al. , found that DMSO treatment potentiated the effect of cisplatin and killed more sensory hair cells than treatment with cisplatin alone. They interpreted their results as DMSO could enhance cisplatin cytotoxicity by facilitating cisplatin entry into cells, increasing its intracellular concentration and likelihood of binding to DNA. In light of these findings the goal of this study is to examine the possible effect of DMSO pretreatment in enhancing the antitumor activity of CIS by examining CIS antitumor activity, apoptosis induction, cell cycle distribution and cisplatin cellular uptake into tumor cells. In addition, examining the possible renal protective effect of DMSO against CIS triggered nephrotoxicity.
Drugs and chemicals
Cisplatin (CIS) and dimethylsulfoxide (DMSO) were purchased from Sigma Aldrich Co. (Saint Louis, Missouri, USA). The stock solution of both drugs (dissolved in phosphate buffer saline (PBS) and preserved at −20 °C. The solutions were diluted in normal saline immediately before each experiment to the desired final concentration.
Animals and tumor
Female Swiss albino mice (8 weeks of age, 20–22 g body weight) and Female Wistar albino rats (8–10 weeks of age, 180–200 g body weight) were obtained from King Fahd Medical Research center, King Abdulaziz University, Jeddah, Saudi Arabia. The animals were acclimatized for 1 week before each experiment. A commercial balanced diet and water ad libitum were provided throughout the experiment. The Ehrlich ascites carcinoma cells (EAC) cells was obtained through the courtesy of National cancer institute (Cairo, Egypt) and maintained in our laboratory by weekly I.P. transplantation of 2.5 × 106 cells/mouse. This study was approved by the Institutional ethical committee of King Abdulaziz hospital.
Evaluation of antitumor activity
The effect of DMSO on the antitumor activity of CIS against the growth of EAC was evaluated using the modified regimen of Donenko et al. . Ehrlich ascites carcinoma cells were inoculated i.p. into forty swiss albino mice (20–22 g) 2.5 × 106 cells/mouse. Twenty-four hours later, mice were equally divided into four groups. Group I injected with normal saline i.p. (0.2 ml/20 gm) and served as control group. Group II administered with CIS (4.5 mg/kg i.p.) while group III received a single dose of DMSO (50 %, 2 ml/kg i.p.). Group IV received DMSO followed by cisplatin (4.5 mg/kg i.p.) 2 h later. Average survival days of mice and long term survivors are defined as the mice survived to the end of the experiment (45 days) with no apparent tumor.
Assessment of tumor weight
Ehrlich ascites carcinoma cells were collected from the ascitic fluid of female Swiss albino bearing mice 8–10 days old ascites tumor. 1 × 106 EAC cells were injected intramuscularly in right thigh of female Swiss albino mice selected for the experiment on day 0. The next day, animals were randomized and divided into four groups each treatment group contains 10 animals. Treatment with DMSO and/or Cisplatin was proceed as the above paragraph.
On day 18, tumor bearing thigh of each animal was shaved and longest and shortest diameters of the tumor were measured with the help of Vernier Caliper. Tumor weight of each animal was calculated using the following formula:
The percent tumor growth inhibition was calculated on day 18 by comparing the average values of treated groups with that of tumor bearing control group.
Measurement of cisplatin cellular uptake
EAC were inoculated i.p. into 20 Swiss albino mice (20–22 g) 10 × 106 cells/mouse. Twenty-four hours later mice were divided into two groups (10 mice each). Group I animals were treated with cisplatin (4.5 mg/kg, i.p.). Group II animals were treated with 50 % DMSO (2 ml/kg, i.p.) followed by cisplatin injection (4.5 mg/kg, i.p) 2 h. Later. Animals were sacrificed by cervical dislocation 24 h. after treatment then the tumor cells were withdrawn and washed twice with PBS then the cells were counted. For drug uptake analysis, cells (1 × 106) were suspended in 1 % HNO3 for 24 h. at 70 °C to be digested. Lysed cells were analyzed by ICP-MS (Thermo scientific, iCAP 6000 series; USA). Provides a quantitative analysis of the concentration of an element in aqueous solution .
Assay of apoptosis
Apoptosis cells were quantified by annexin V-FITC-propodium iodide double staining, using an annexin V-FITC apoptosis detection kit. EAC were inoculated i.p. into 40 Swiss albino mice (20–22 g) 10 × 106 cells/mouse. Twenty-four hours later mice were divided into four groups (10 mice each). Group I animals were treated with normal saline i.p. (2 ml/kg, i.p.) and served as control group. Group II animals were treated with 50 % DMSO (2 ml/kg, i.p.). Group III animals were received cisplatin (4.5 mg/kg, i.p.). Group IV animals were treated with 50 % DMSO (2 ml/kg, i.p.) followed by cisplatin (4.5 mg/kg, i.p.) 2 h later.
Animals were sacrificed by cervical dislocation 24 h after treatment then the tumor cells were withdrawn and washed twice with PBS and resuspended in 100 µl annexin V incubation reagent prepared by mixing (binding buffer 10×, PI, annexin V-FITC and deionized water) for each sample. The solution was incubated in the dark for 15 min at RT. Then 400 μl 1× of binding buffer were added to each sample and process by flow cytometry (NAVIOS Beckman Coulter, USA) within 1 h for maximal signal.
Cell cycle analysis
Ehrlich ascites carcinoma cells were inoculated i.p. into sixty swiss albino mice (20–22 g) 10 × 106 cells/mouse and processed as mentioned in the paragraph of Apoptosis. Tumor cells were obtained 24 h. after cisplatin treatment. Cell cycle analysis was performed using flow cytometer (Becto Dicknson, BD, FACScalbur, USA according to the method of Pozarowiski P., Darzynkiewicz .
Effect of CIS and/or DMSO on kidney function and renal histopathology
Twenty male wister rat were divided into four equal groups, 5 animals each. Group I animals were received normal saline i.p. (2 ml/kg, i.p.) and reserved as control group. Group II animals were treated with 50 % DMSO (2 ml/kg i.p.). Group III animals were treated with cisplatin (7.5 mg/kg, i.p.). Finally, Group IV animals were treated with 50 % DMSO (2 ml/kg, i.p.) followed by cisplatin (7.5 mg/kg, i.p.) 2 h later. At the end of the experiment period (72 h), rats were anesthetized and blood samples were collected from the ophthalmic artery in the orbital rim and rapidly centrifuged for serum separation that was stored at −80 °C to evaluate serum urea and creatinine levels.
The dissected rat kidney was cut into small pieces and immersed immediately in 10 % neutral buffered formalin, for light microscope study.
Evaluation of serum creatinine concentration
The serum creatinine concentration was estimated by alkaline picrate method using the commercially available kit .
Evaluation of serum urea concentration
The blood urea was estimated by Berthelot method  using the commercially available kit.
Statistical analysis was performed using SPSS (Statistical package of social science, version 16).One way analysis of variance (ANOVA) followed by least significant difference (LSD) for post hoc analysis was used for multiple comparisons. Statistical significance was acceptable to a level of p ≤0.05.
Survival of tumor bearing mice
Table 1 shows the survival of Erlich ascites carcinoma bearing mice after treatment with cisplatin and/or DMSO. Tumor-bearing control mice showed a mean survival time of 17 days, whereas,administration of a single dose of cisplatin (4.5 mg/kg, i.p.) increased the mean survival time to 37 days, with 50 % long term survivors. Treatment with 50 % DMSO 2 h. before increased the mean survival time of tumor-bearing mice to 43 days with 80 % survivors.
Assessment of tumor weight
Table 2 shows Anti-tumor efficacy of cisplatin and/or DMSO which was expressed as the percentage of tumor growth inhibition calculated on day 18 by comparing the average tumor weight of treated groups with that of tumor bearing control group. Tumor growth in saline treated animals was taken to be 100 %. Cisplatin treatment (4.5 mg/kg, i.p.) showed 61 % inhibition of tumor growth. Pretreatment with DMSO 50 % (2 ml/kg, i.p.) showed 80 % inhibition of growth of solid EAC.
Effect of cisplatin and/or DMSO on apoptosis induction in EAC cells
The percentage of early apoptotic cells (Annexin V-positive cells) were dramatically increased after treatment with cisplatin in comparison to the control cells (% early apoptosis cells). Also, pretreatment with 50 % DMSO (2 ml/kg, i.p.) followed by cisplatin (4.5 mg/kg, i.p.) increased the percentage of early apoptotic cells (Annexin V-positive cells) significantly compared with EAC cells withdrawn from animals treated with cisplatin (4.5 mg/kg, i.p.) alone Fig. 1.
Effect of CIS and/or DMSO treatment on cell cycle phase progression in ehrlich cells
Figure 2 shows the percent distribution of G0/G1, S, and G2/M of tumor cells 24 h after treatment with cisplatin and/or DMSO. Cisplatin treatment (4.5 mg/kg, i.p.) accumulated the cells in G0/G1 phase by 42 %. Pretreatment with 50 % DMSO (2 ml/kg, i.p.) followed by cisplatin (4.5 mg/kg, i.p.) significantly increase the accumulation in G0/G1 phase by 57 %.
Cisplatin cellular uptake in Ehrlich ascites cells
Table 3 shows the cellular level of CIS in Ehrlich ascites cells after a single dose of cisplatin (4.5 mg/kg, i.p.) and/or DMSO 2 h before (50 %, 2 ml/kg, i.p.). All the time point tested showed that DMSO pretreatment increased the cellular uptake of CIS in the tumor cells (Table 3).
Effects of DMSO on cisplatin induced-nephrotoxicity
Table 4 represents the kidney function (serum creatinine and urea) of treated animals. DMSO treatment had no significant effect on urea and serum creatinine levels compared with control group. Serum urea and creatinine average levels were significantly elevated in cisplatin treated animals by about 237 and 3 mg/dl, respectively. While DMSO pretreatment of cisplatin treated animals return both urea and creatinine levels nearly to normal values (73 and 0.73 mg/dl, respectively).
Figures (3, 4) showed normal kidney tissue with no abnormalities when the animals treated with normal saline or DMSO, respectively. While treatment with cisplatin (7.5 mg/kg, i.p.), there were marked necrosis in proximal tubules and degeneration of the tubular epithelial cells (Fig. 5). Pretreatment with 50 % DMSO(2 ml/kg, i.p.), decreased the cisplatin induced tubular necrosis (Fig. 6) comparing with cisplatin treated animals.
Cisplatin is the most widely used cytotoxic drug in the treatment of many kinds of tumors either alone or in combination with other cytocidal agents. However, its clinical uses are limited by its detrimental adverse effects including nephrotoxicity. Chemosensitization is one strategy that may be used to decrease the anti-tumor dose and toxicity. A variety of approaches have been tried to enhance the cytotoxic effects of chemotherapeutic agents and at the same time decreased their toxicity. Among the potential chemosensitizer is dimethyl sulfoxide which has chemopreventive  and cytotoxic activity . This study focused on investigating whether DMSO would enhance the cisplatin cytotoxic effects against the growth of EAC cells in vivo and the possible protective effect against cisplatin induced nephrotoxicity. The possible modulatory mechanisms were also explored by studying the changes of apoptosis induction, cell cycle phase distribution and cisplatin cellular uptake after treatment with cisplatin in the presence and absence of DMSO. Preliminary studies with different DMSO doses showed that a dose level of 2 ml/kg (2 gm/kg) was of great efficacy and little organ toxicity.
The current study showed that the pretreatment of tumor bearing mice with 50 % DMSO (2 ml/kg, i.p.), significantly enhances the cytotoxic activity of cisplatin against the growth of EAC cells by 1.6-fold increase in the long term survivor compared with animals treated with cisplatin alone (Table 1).
It is well known that cisplatin induced formation of intra and inter-DNA strand cross linkage lead to severe local distortion in the DNA double helical structure lead to cell death [16–18]. For more conformation, the study showed that the treatment of solid Ehrlich tumor bearing mice with 50 % DMSO before cisplatin treatment increased the percentage of inhibition of solid tumor growth to 80 % compared with 61 % in cisplatin treated animals (Table 2).
The above mentioned results have been confirmed by the observed increase in cisplatin cellular uptake after DMSO treatment. Pretreatment with DMSO lead to almost twofolds increase in the cisplatin accumulation ratios in EAC cells compared with corresponding cells treated with cisplatin alone (Table 3). It has been reported that DMSO induces membrane thinning, increases the fluidity of the membrane hydrophobic core and induces transient water pores into the membrane which may facilitate the uptake of cisplatin into tumor cells [5, 19, 20]. This may lead to more cisplatin uptake and consequently lead to cell death. The current study agree with that reported by Uribe et al. , who found that DMSO treatment potentiated the effect of cisplatin and killed more sensory hair cells than treatment with cisplatin alone. They also interpreted their results as DMSO could enhance cisplatin cytotoxicity by facilitating cisplatin entry into cells, increasing its intracellular concentration and likelihood of binding to DNA. This finding has been observed in our study where DMSO treatment increased cellular uptake and cytotoxicity of cisplatin against the growth of tumor cells. DMSO may bind to cisplatin after tumor cell entry, where cisplatin-DMSO adducts have greater affinity for DNA, potentiating cisplatin cytotoxicity . Also, our results supports Pommier et al.  who reported that DMSO could sensitize cancer cells to the apoptosis or growth arrest and synergistically increases the cytotoxicity of antineoplastic agents against five different human tumor reference cell lines. Moreover, our results showed a significant increase in percentages of early apoptosis in the EAC cells treated with cisplatin and DMSO, compared with cells treated with cisplatin alone (Fig. 1).
In contrary to our previous results, Hall et al.  showed inhibition of cytotoxicity and ability to initiate cell death when cisplatin dissolved in DMSO. This discrepancy could be refuted as their study depended on formation of new chemical compound between cisplatin and DMSO, while the principle of our study depends on pretreatment of animals with DMSO before cisplatin. This preempt administration allowed DMSO to distribute into EAC cells and to exerts its possible modulation effect on different targets such as cell membrane and mitochondrial membranes, apoptotic signaling proteins and cell cycle regulators. The current results showed that the pretreatment of the tumor cells withdrawn from animals treated with DMSO before cisplatin, showed a significant increase in the arrested cells in G0 compared with cells treated with cisplatin alone (Fig. 2). This could be due to the capability of DMSO to modulate several cell signaling molecules, including cell survival proteins, drug transporters and cell proliferative proteins and its ability to interfere with the expression of anti-apoptotic signals [15, 24]. It is well known that DNA damage caused by different cytotoxic agents, induced cell cycle arrest at G1, S, G2, thereby preventing replication of damaged DNA or aberrant mitosis which if not repaired, may result in either tumorigenesis or apoptosis . Our results suggested that DMSO induce apoptosis dominantly in a wide variety of tumor cells through targeting many of the cisplatin apoptotic protein as overexpression of P53 , P21 , Bcl-2 and Bcl2/bax ratio  This will able DMSO to potentiate the cisplatin induced-apoptosis and lead to more killing effect. In animals studies the acute nephrotoxicity induced by cisplatin was associated with high level of serum creatinine and blood urea nitrogen .
In the current study, rats treated with cisplatin alone showed a significant increase in the levels of serum creatinine and blood urea levels, while in the DMSO pretreated animals the levels nearly return to normal (Table 4).
Previous results by Ali and Mousa,  have also reported that DMSO was effective in completely preventing the development of signs of nephrotoxicity of nephrotoxic drug gentamycin (50 mg/kg), in treated rats. In harmonization with our results they stated that treatment with DMSO alone did not alter significantly any of the renal function tests studied. Our biochemical results have been confirmed by histopathological studies of the kidneys of cisplatin treated rats in presence and absence of DMSO. Histopatholgical evaluation in this study showed that cisplatin treatment causes a marked necrosis in proximal tubules and degeneration of the tubular epithelial cells, while pre-treatment with DMSO minimized these histopathological deteriorations (Figs. 5, 6). Moreover, electron microscopic investigation of rat’s kidneys tissues after cisplatin treatment in presence and absence of DMSO confirmed the histopathological findings (data not shown). These results are in a good agreement with Jones et al. [12, 14] and Santos et al.  who reported the protective effect of DMSO against cisplatin-induced kidney tissues damage. They referred this protective effect to antioxidant properties of DMSO which result in reserving glutathione and consequently introduce a perfect nephroprotection.
In conclusion, it seems that dimethyl sulfoxide could potentiate the cytotoxic activity of cisplatin by many different molecular mechanisms which need to be carefully investigated to know the exact mechanisms of synergistic interaction between DMSO and cispaltin. Also DMSO could be a proper agent to be applied clinically in many other situations with a dose up to one gram per kilogram body weight.
Desoize B, Madoulet C. Particular aspects of platinum compounds used at present in cancer treatment. Crit Rev Oncol Hematol. 2002;42:317–25.
Perez RP. Cellular and molecular determinants of cisplatin resistance. Eur J Cancer. 1998;34:1535–42.
Lebwohl D, Canetta R. Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer. 1998;34:1522–34.
Sanmartin-Suarez C, Soto-Otero R, Sanchez-Sellero I, Mendez-Alvarez E. Antioxidant properties of dimethyl sulfoxide and its viability as a solvent in the evaluation of neuroprotective antioxidants. J Pharmacol Toxicol Methods. 2011;63:209–15.
Jacob SW, Bischel M, Herschler RJ. Dimethyl sulfoxide: effects on the permeability of biologic membranes (preliminary report). Curr Ther Res Clin Exp. 1964;6:193–8.
Stoughton RB, Fritsch W. Influence of dimethylsulfoxide (DMSO) on human percutaneous absorption. Arch Dermatol. 1964;90:512.
Kligman AM. Dimethyl sulfoxide. 2. JAMA. 1965; 193: 923–8 (concl).
Uribe PM, Mueller MA, Gleichman JS, Kramer MD, Wang Q, Sibrian-Vazquez M, Strongin RM, Steyger PS, Cotanche DA, Matsui JI. Dimethyl sulfoxide (DMSO) exacerbates cisplatin-induced sensory hair cell death in zebrafish (Danio rerio). PLoS One. 2014;8:e55359.
Donenko FV, Efferth T, Mattern J, Moroz LV, Volm M. Resistance to doxorubicin in tumor cells in vitro and in vivo after pretreatment with verapamil. Chemotherapy. 1991;37:57–61.
Barr MP, Gray SG, Hoffmann AC, Hilger RA, Thomale J, O’flaherty JD, Fennell DA, Richard D, O’leary JJ, O’byrne KJ. Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature. PLoS One. 2013;8:e54193.
Pozarowiski P, Darzynkiewicz Z. Analysis of cell cycle by flowcytometry method. Mol Biol. 2004;281:301–11.
Taussky RW, Taussky HH. ON the colorimetric determination of creatinine by the jaffe reaction. J Biol Chem. 1945; 10.
Fawcett JK, Scott JE. A rapid and precise method for the determination of urea. J Clin Pathol. 1960;13:156–9.
Jones MM, Basinger MA, Field L, Holscher MA. Coadministration of dimethyl sulfoxide reduces cisplatin nephrotoxicity. Anticancer Res. 1991;11:1939–42.
Trubiani O, Ciancarelli M, Rapino M, di Primio R. Dimethyl sulfoxide induces programmed cell death and reversible G1 arrest in the cell cycle of human lymphoid pre-T cell line. Immunol Lett. 1996;50:51–7.
Ciccarelli RB, Solomon MJ, Varshavsky A, Lippard SJ. In vivo effects of cis- and trans-diamminedichloroplatinum(II) on SV40 chromosomes: differential repair, DNA-protein cross-linking, and inhibition of replication. Biochemistry. 1985;24:7533–40.
Eastman A. The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. Pharmacol Ther. 1987;34:155–66.
Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov. 2005;4:307–20.
Liu J, Yoshikawa H, Nakajima Y, Tasaka K. Involvement of mitochondrial permeability transition and caspase-9 activation in dimethyl sulfoxide-induced apoptosis of EL-4 lymphoma cells. Int Immunopharmacol. 2001;1:63–74.
Gurtovenko AA, Anwar J. Modulating the structure and properties of cell membranes: the molecular mechanism of action of dimethyl sulfoxide. J Phys Chem B. 2007;111:10453–60.
Sundquist WI, Ahmed KJ, Hollis LS, Lippard SJ. Solvolysis reactions of cis- and trans-diamminedichloroplatinum(II) in dimethyl sulfoxide. Structural characterization and DNA binding of trans-bis(ammine)chloro(DMSO)platinum(1+). Inorg Chem. 1987;26:1524–8.
Pommier RF, Woltering EA, Milo G, Fletche WS. Synergistic cytotoxicity between dimethyl sulfoxide and antineoplastic agents against ovarian cancer in vitro. Am J Obstet Gynecol. 1988;159:848–52.
Hall MD, Telma KA, Chang KE, Lee TD, Madigan JP, Lloyd JR, Goldlus IS, Hoeschele JD, Gottesman MM. Say no to DMSO: dimethylsulfoxide inactivates cisplatin, carboplatin, and other platinum complexes. Cancer Res. 2014;74:3913–22.
Takase K, Sawai M, Yamamoto K, Yata J, Takasaki Y, Teraoka H, Tsukada K. Reversible G1 arrest induced by dimethyl sulfoxide in human lymphoid cell lines: kinetics of the arrest and expression of the cell cycle marker proliferating cell nuclear antigen in Raji cells. Cell Growth Differ. 1992;3:515–21.
Yan X, Fraser M, Qiu Q, Tsan BK. Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner. Gynecol Oncol. 2006;102:348–55.
Ponzio G, Loubat A, Rochet N, Turchi L, Rezzonico R, FarahiFar D, Dulic V, Rossi B. Early G1 growth arrest of hybridoma B cells by DMSO involves cyclin D2 inhibition and p21[CIP1] induction. Oncogene. 1998;17:1159–66.
Zhang JG, Lindup WE. Differential effects of cisplatin on the production of NADH-dependent superoxide and the activity of antioxidant enzymes in rat renal cortical slices in vitro. Pharmacol Toxicol. 1996;79:191–8.
Ali BH, Mousa HM. Effect of dimethyl sulfoxide on gentamicin-induced nephrotoxicity in rats. Hum Exp Toxicol. 2001;20:199–203.
Santos NC, Figueira-Coelho J, Martins-Silva J, Saldanha C. Multidisciplinary utilization of dimethyl sulfoxide: pharmacological, cellular, and molecular aspects. Biochem Pharmacol. 2003;65:1035–41.
AMO, AG, ZAD, SEA, MAMO sharing in experimental work and writing the manuscript.MFA did the flow cytometric analysis and interpreted the results and WSR investigated the pathological changes in the kidney. All authors read and approved the final manuscript.
The present study was funded by a grant from King Abdulaziz City for Science and Technology Research, Saudi Arabia (No. 266-34 ط.أ).
The authors declare that they have no competing interest.
About this article
Cite this article
Osman, A.M., Alqahtani, A.A., Damanhouri, Z.A. et al. Dimethylsulfoxide excerbates cisplatin-induced cytotoxicity in Ehrlich ascites carcinoma cells. Cancer Cell Int 15, 104 (2015). https://doi.org/10.1186/s12935-015-0258-1